Gene Therapy of Parkinson’s Disease

Malik A*, Tabbasum S, Hanif Z and Jabeen N

Department of Bioinformatics and technology, International Islamic University, Islamabad, Pakistan, Postal Code 44000

Abstract

Parkinson’s is second most common neurological disorder in the world having both sporadic and familial cases. Present Parkinson’s disease genetics taxonomy specifies 18 chromosomal regions that are also called chromosomal locus which are termed PARK. Gene therapy i.e., Use of genes as medicine, is effective and newly discovered treatment of many Central nervous system disorders including Parkinson’s disease. Direct injection was also performed but it does not give suitable results. So, scientist feel need of using different vectors for efficient delivery of genes in Central nervous system. Hence gene therapy of Parkinson’s disease involves use of both viral and non-viral vectors but viral vectors shows efficient results. Frequently used vectors for therapy of Parkinson’s disease are Lentivirus and adenovirus associated virus. Using these vectors many successful experiments are performed on different animals. Parkin, Glial cell-derived neurotrophic factor (GDNF) and alpha synuclein are some of the successful products for therapy of Parkinson’s disease.

Keywords: Parkinson’s disease; Genetics; Gene therapy; Lentivirus

Introduction

Parkinson’s disease is a very common and widely spread neurological disorder. It is very common among people of all contests and topographical areas [1]. Parkinson’s disease is the second most public neurodegenerative sickness next to Alzheimer’s disease [2]. Symptoms are given in (Table 1).

Epidemiology and risks

Male is more prone to this disease than females. Men to women ration of Parkinson’s disease is 3:2 [2]. Yearly occurrence rate range is from 8.6 to 19 per 100,000 [2,3]. An occurrence of 1%-2% in the people elder than 60–65 year, or 0.3% in the over-all inhabitants [2,4], with frequency rates fluctuating from 65.6 to 12,500 per 100,000 population [5]. More than 4 million Parkinson’s disease patients were there in the globe in year 2005 [6]. It befalls irregularly below 40 years of age, onset early increasing the possibility that hereditary reasons might be involved [2,7].

Genetics

Research in Parkinson’s disease shows that many monogenic form of ailments and genetics is involved in the aggregating the risk of Parkinson’s disease. Monogenic forms that are initiated by a single mutation which follows dominant or recessive inherited genetics. They mutually cause 30% of the familial and it was also found in 3% to 5% of the sporadic cases. Present Parkinson’s disease genetics taxonomy specifies 18 chromosomal regions that are also called chromosomal locus which are termed PARK. Confirmed PARK designated gene loci mode of inheritance etc. Are described in (Table 2) [8].

Gene therapy: An expected treatment of Parkinson’s disease

Gene therapy (use of genes as medicines) is basically used to correct defective genes responsible for genetic disorder [9,10]. Gene medical care is the use of nucleic acids as medication [11]. Thus, as for any drug, its application is going to be primarily restricted to therapeutic uses. Four classes or sorts of factor medical care are defined: (i) corporeal gene therapy, (ii) corporal genetic enhancement, (iii) germ line factor gene therapy, and (iv) germ line genetic enhancement [12].

About 4,000 sicknesses have been traced which are caused by gene disorders. Modern-day and viable candidates for gene remedy consist

<table>
<thead>
<tr>
<th>Symbol</th>
<th>Gene locus</th>
<th>Gene</th>
<th>Inheritance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Park 1</td>
<td>4q21–22</td>
<td>SNCA</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td>Park 2</td>
<td>6q25.2–q27</td>
<td>Parkin</td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td>Park 6</td>
<td>1p35–p36</td>
<td>PINK1</td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td>Park 7</td>
<td>1p36</td>
<td>DJ-1</td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td>Park 8</td>
<td>12q12</td>
<td>LRRK2</td>
<td>Autosomal dominant</td>
</tr>
<tr>
<td>Park 9</td>
<td>1p36</td>
<td>ATP13A2</td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td>Park 10</td>
<td>1p32</td>
<td>Unknown</td>
<td>Risk factor</td>
</tr>
<tr>
<td>Park 14</td>
<td>22q13-1</td>
<td>PLA2G6</td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td>Park 15</td>
<td>22q12–q13</td>
<td>FBX07</td>
<td>Autosomal recessive</td>
</tr>
<tr>
<td>Park 16</td>
<td>1q32</td>
<td>Unknown</td>
<td>Risk factor</td>
</tr>
</tbody>
</table>

*Corresponding author: Ayesha Malik, Department of Bioinformatics and technology, International Islamic University, Islamabad, Pakistan, Postal Code 44000, Tel: 9242111000010; E-mail: ayesha.msbt226@iiu.edu.pk

Received January 23, 2017; Accepted February 23, 2017; Published February 27, 2017


Copyright: © 2017 Malik A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

<table>
<thead>
<tr>
<th>Motor symptoms</th>
<th>Non-motor symptoms</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bradykinesia:</td>
<td>Neuropsychiatric features:</td>
</tr>
<tr>
<td>Sluggish drive</td>
<td>Anxiety, panic attacks, Mood disorder, depression, illusion, delusion, dementia</td>
</tr>
<tr>
<td>Loss of breadth/rapidity</td>
<td></td>
</tr>
<tr>
<td>Reduction of muscular power (paresis)</td>
<td>Sleep complaints:</td>
</tr>
<tr>
<td>Spasticity</td>
<td>Insomnia</td>
</tr>
<tr>
<td>Rest tremor</td>
<td>Restless leg syndrome</td>
</tr>
<tr>
<td>Inelasticity of muscles</td>
<td>Behaviour malady</td>
</tr>
<tr>
<td>Postural and gait damage:</td>
<td>Daytime drowsiness</td>
</tr>
<tr>
<td>Curved posture</td>
<td></td>
</tr>
<tr>
<td>Reduction in arm swipe</td>
<td>Sensory dysfunction:</td>
</tr>
<tr>
<td>Damage Mobility and turning</td>
<td></td>
</tr>
<tr>
<td>Damage Mobility and turning</td>
<td></td>
</tr>
</tbody>
</table>

Table 1: Symptoms of Parkinson’s disease [1].

Table 2: Parkinson’s disease related loci nominated by PARK [8].
of most cancers, AIDS, cystic fibrosis, Parkinson’s and Alzheimer’s sicknesses, amyotrophic lateral sclerosis (Lou Gehrig’s ailment), cardiovascular ailment and arthritis [13].

Methods of Gene Delivery to Target Cells

Non-viral methods

Various strategies are developed for transfer of gene to the target cells that embody infective agent vectors, and non-viral systems. Non-viral strategies that are marginally used for gene transfer to the central system (CNS), comprise chemical and physical strategies, like gene gun or electroporation. The power of infective agent vectors to convert nondividing cells is of crucial importance within the context of Parkinson’s disease gene medical care [14].

Research efforts have yielded many non-viral strategies cistron transfer like electroporation (creation of electrical field iatro-), magnetofection (usage of magnetic unit to disturb cell membrane), and receptor mediate cistron transfer like electroporation. The power of infective agent vectors to convert nondividing cells is of crucial importance within the context of Parkinson’s disease gene medical care [14].

Viral methods

Viral vectors are built from wild-type viruses by eliminating the genes, crucial to their duplication, from their genome. The vectors are thus able to infect cells and transmission their genetic material into the nucleus, however they are not able to duplicate themselves within the host cells. This side is crucial for vector safety, because it removes virus pathogenicity and stops uncontrolled dispersal of transgene delivery initiated by vector replication within the host animal.

Here we are going to target vectors derived from adeno-associated virus (AAV) and lentivirus, as they’re the sole ones that have touched the clinic for CNS cistron medical aid trials [14].

Lentivectors: Lentiviruses, belong to family Retroviridae. They are enveloped viruses whose genome contains single stranded RNA which encodes structural proteins. Their genome consists of four genes i.e. Gag, pol, tat, and rev. The highest packaging capability of lentivectors is eighteen kilo bases (KB), however the foremost economical packaging is attained with genomes within vary of half-dozen to nine KB [14].

AAV-based vectors: Aavs belongs of family paroviridae family. They are small and non-enveloped viruses. Their genome size is 4.7 kb AAV which contains single-stranded DNA. This DNA encoding four proteins which are very vital for replication and packaging (rep gene), it also encodes three capsid proteins (cap gene) which are enclosed by two inverted terminal repeats (ITR). AAV vectors are best vectors to transfer genes in the CNS. They provide us with very good safety profile, and effective transduction and strong expression of neurons. Beside all this there is also a limitation of AAV that is the restricted packaging volume (4.7 kb) that excludes the incorporation of huge genes [14].

Discussion

Effective gene therapy mediated products used for Parkinson’s disease treatment

Parkin [15] GDNF (Gial cell line-derived neurotropic factor) [16] and alpha synuclein [17] are the three-gene therapy based product of Parkinson’s disease.

Gial cell line-derived neurotropic factor (GDNF) ropes development and existence of dopaminergic (DA) neurons. Ad vector-mediated GDNF gene therapy might sluggish the DA neuronal cell harm in individuals with Parkinson’s disease [17-24].

Parkin is gene product of familial Parkinson’s disease. Viral vectors for Parkin manifestation have revealed neuro-protective properties in numerous animal models of Parkinson’s disease [15].

Conclusion

Parkinson’s disease is a serious CNS disorder which need treatment on urgent basis as it has many symptoms which becomes worst with the passage of time (Table 3). Its prevalence is increasing and it has both genetic and sporadic factors involved. Symptomatic therapies show no effective treatment so researched move toward gene therapy. Production of novel vectors will increase the efficiency. Different product has been designed using gene therapy for the treatment of Parkinson’s disease including Parkin, GDNF and alpha synuclein. But still there is need to further research in this field especially there is strong need to implement these Products on more Humans and design new vectors and products.

References